Variability in melanoma post-treatment surveillance practices by country and physician specialty: A systematic review

Melanoma Research

Volumn 22, Issue 5, 2012, Pages 376-385

  Cromwell, Kate D ^a   Ross, Merrick I ^a   Xing, Yan ^a   Gershenwald, Jeffrey E ^a   Royal, Richard E ^a   Lucci, Anthony ^a   Lee, Jeffrey E ^a   Cormier, Janice N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

melanoma; patient care; post treatment surveillance; systematic review

Indexed keywords

AFRICAN AMERICAN; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; CAUCASIAN; CONSENSUS; DISEASE SEVERITY; DISEASE SURVEILLANCE; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE DISPARITY; HUMAN; IMAGING; LABORATORY TEST; MELANOMA; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE; RECURRENCE RISK; SELF EVALUATION; SKIN EXAMINATION; SPECIALIZATION; SURVIVAL TIME; UNITED KINGDOM;

FOLLOW-UP STUDIES; HUMANS; MEDICINE; MELANOMA; PATIENT CARE; PHYSICIAN'S PRACTICE PATTERNS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; SKIN NEOPLASMS;

EID: 84866234811     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328357d796     Document Type: Article

References (108)

1. World Cancer Research Fund International. GLOBOCAN 'General world cancer statistics'. London: World Health Organization; 2008.
2. Howlader N, Am N, Krapcho M, et al. SEER Cancer Statistics Review 1975-2009. Bethesda, MD: National Cancer Institute; http://seer.cancer.gov/csr/ 1975-2009-pops09/; 2012.
3. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer 2005; 92:241-245. (Pubitemid 40343136)
4. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003; 53:5-26.
5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
6. Benvenuto-Andrade C, Oseitutu A, Agero AL, Marghoob AA. Cutaneous melanoma: surveillance of patients for recurrence and new primary melanomas. Dermatol Ther 2005; 18:423-435. (Pubitemid 43096616)
7. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998; 67:228-233. (Pubitemid 28196912)
8. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70. (Pubitemid 34779439)
9. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, Hunter JA. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Br J Dermatol 1999; 140:249-254. (Pubitemid 29111351)
10. McEwan L, Smith JG, Matthews JP. Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. Plast Reconstr Surg 1990; 86:527.
11. Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, et al. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol 2010; 17:2015-2023.
12. Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 2010; 116:2234-2241.
13. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997; 79:2361-2370. (Pubitemid 27251019)
14. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005; 294:1647-1654. (Pubitemid 41407357)
15. DiFronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 1999; 6:705-711.
16. DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer 2001; 91:1520-1524. (Pubitemid 32319263)
17. Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol 1998; 39:422-427. (Pubitemid 28417378)
18. Levi F, Randimbison L, Te VC, La Vecchia C. High constant incidence rates of second cutaneous melanomas. Int J Cancer 2005; 117: 877-879. (Pubitemid 41598843)
19. Schmid-Wendtner MH, Baumert J,Wendtner CM, Plewig G, Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001; 145:981-985. (Pubitemid 34204474)
20. Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with cutaneous malignant melanoma: a populationbased study in Sweden. Br J Cancer 1996; 73:255-259. (Pubitemid 26028343)
21. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 2007; 14:1924-1933. (Pubitemid 46870937)
22. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995; 221:566-569, discussion 569-571.
23. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21:520-529. (Pubitemid 46606483)
24. Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, et al. Costeffectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995; 191:199-203.
25. Einwachter-Thompson J, MacKie RM. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5mm thick at diagnosis. Br J Dermatol 2008; 159:337-341. (Pubitemid 352009840)
26. Hall JH, Lupton ES. Office management of malignant melanoma: a report of 132 patients. Cutis 1979; 24:453-456. (Pubitemid 10190646)
27. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010; 28:3042-3047.
28. Moore A, Edwards J, Barden J, McQuay H. Bandolier's little book of pain. Oxford, England: Oxford University Press; 2003.
29. Kersey PA, Iscoe NA, Gapski JA, Osoba D, From L, DeBoer G, Quirt IC. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 1985; 72:614-617. (Pubitemid 15047613)
30. Regan MW, Reid CD, Griffiths RW, Briggs JC. Malignant-melanoma, evaluation of clinical follow up by questionnaire survey. Br J Plast Surg 1985; 38:11-14. (Pubitemid 15105387)
31. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166:497-502.
32. Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28:45-49.
33. Slingluff CL Jr., Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992; 70:1917-1927.
34. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993; 5:174-180. (Pubitemid 23218467)
35. Florey CV, Yule B, Fogg A, Napier A, Orbell S, Cuschieri A. A randomized trial of immediate discharge of surgical patients to general practice. J Public Health Med 1994; 16:455-464.
36. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995; 274:1703-1705.
37. Moloney DM, Gordon DJ, Briggs JC, Rigby HS. Recurrence of thin melanoma: how effective is follow-up? Br J Plast Surg 1996; 49: 409-413. (Pubitemid 26302626)
38. Brobeil A, Rapaport D, Wells K, Cruse CW, Glass F, Fenske N. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol 1997; 4:19-23.
39. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 1997; 80:1052-1064. (Pubitemid 27427604)
40. Sylaidis P, Gordon D, Rigby H, Kenealy J. Follow-up requirements for thick cutaneous melanoma. Br J Plast Surg 1997; 50:349-353. (Pubitemid 27312145)
41. Poo-HwuWJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Followup recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999; 86:2252-2258. (Pubitemid 30010365)
42. Kittler H, Weitzdorfer R, Pehamberger H, Wolff K, Binder M. Compliance with follow-up and prognosis among patients with thin melanomas. Eur J Cancer 2001; 37:1504-1509. (Pubitemid 32744680)
43. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002; 87:151-157.
44. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6:608-621. (Pubitemid 41051939)
45. Hengge UR, Wallerand A, Stutzki A, Kockel N. Cost-effectiveness of reduced follow-up in malignant melanoma. J Dtsch Dermatol Ges 2007; 5:898-907. (Pubitemid 47546372)
46. Chakera AH, Hansen LB, Lock-Andersen J, Drzewiecki KT, Hesse B. In-transit sentinel nodes must be found: implication from a 10-year followup study in melanoma. Melanoma Res 2008; 18:359-364.
47. Francken AB, Accortt NA, Shaw HM, Colman MH,Wiener M, Soong SJ, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008; 95:1401-1407.
48. Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 2008; 15:2206-2214.
49. Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD, Ollila DW, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 2009; 16:941-947.
50. Murchie P, Delaney EK, Campbell NC, Hannaford PC. GP-led melanoma follow-up: views and feelings of patient recipients. Support Care Cancer 2009; 18:225-233.
51. Brown RE, Stromberg AJ, Hagendoorn LJ, Hulsewede DY, Ross MI, Noyes RD, et al. Surveillance after surgical treatment of melanoma: futility of routine chest radiography. Surgery 2010; 148:711-716, discussion 716-717.
52. Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res 2010; 20:240-246.
53. Roh MR, Kim J, Chung KY. Treatment and outcomes of melanoma in acral location in Korean patients. Yonsei Med J 2010; 51:562-568.
54. Abbott RA, Acland KM, Harries M, O'Doherty M. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence. Melanoma Res 2011; 21:446-449.
55. DeRose ER, Pleet A, Wang W, Seery VJ, Lee MY, Renzi S, et al. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res 2011; 21:364-369.
56. Hull PR, Piemontesi NG, Lichtenwald J. Compliance with self-examination surveillance in patients with melanoma and atypical moles: an anonymous questionnaire study. J Cutan Med Surg 2011; 15:97-102.
57. Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, et al. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 2011; 253:1211-1215.
58. Leiter U, Buettner PG, Eigentler TK, Brocker EB, Voit C, Gollnick H, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol 2011; 66:37-45.
59. Kovalyshyn I, Dusza SW, Siamas K, Halpern AC, Argenziano G, Marghoob AA. The impact of physician screening on melanoma detection. Arch Dermatol 2011; 147:1269-1275.
60. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993; 5:174-180. (Pubitemid 23218467)
61. Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am 2006; 15:319-330. (Pubitemid 44316694)
62. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Wellington: Sydney and New Zealand: The Cancer Council Australia, Australian Cancer Network, Sydney and New Zealand Guidelines Group; 2008.
63. Thompson JF, Shaw HM, Stretch JR, McCarthy WH, Milton GW. The Sydney Melanoma Unit-a multidisciplinary melanoma treatment center. Surg Clin North Am 2003; 83:431-451. (Pubitemid 36519198)
64. Ugurel S, Enk A. Skin cancer: follow-up, rehabilitation, palliative and supportive care. J Dtsch Dermatol Ges 2008; 6:492-498, quiz 499.
65. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, et al. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 2007; 17:393-399. (Pubitemid 350084995)
66. Garbe C, Schadendorf D. Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 2003; 26:241-246. (Pubitemid 36831212)
67. Dummer R, Hauschild A, Pentheroudakis G. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4):129-131.
68. Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, et al. U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002; 146:7-17.
69. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al. Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg 2010; 63:1401-1419.
70. NCCN clinical practice guidelines in oncology: melanoma. 2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/melanoma.pdf.
71. Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45:579-586. (Pubitemid 32917254)
72. Chu D, Coit DG, Daud A, Dilawari R, Guitart J, Halpern AC, et al. Melanoma: treatment guidelines for patients. Part 2. Dermatol Nurs 2005; 17:191-198.
73. Olson JA Jr, Jaques DP, Coit DG, Hwu WJ. Staging work-up and posttreatment surveillance of patients with melanoma. Clin Plast Surg 2000; 27:377-390, viii. (Pubitemid 30599578)
74. Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol 1994; 20:175-178.
75. Kroon BB, Nieweg OE, Hoekstra HJ, Lejeune FJ. Principles and guidelines for surgeons: management of cutaneous malignant melanoma. European Society of Surgical Oncology Brussels. Eur J Surg Oncol 1997; 23:550-558. (Pubitemid 28059781)
76. Rumke P, van Everdingen JE. Consensus on the management of melanoma of the skin in The Netherlands. Dutch Melanoma Working Party. Eur J Cancer 1992; 28:600-604.
77. Dummer R, Guggenheim M, Arnold AW, Braun R, von Moos R. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2011; 141:w13320.
78. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005; 210:39-44. (Pubitemid 39656718)
79. Durbec F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hedelin G, et al. The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France. Arch Dermatol 2010; 146:240-246.
80. Machet L, Nemeth-Normand F, Giraudeau B, Perrinaud A, Tiguemounine J, Ayoub J, et al. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. Br J Dermatol 2005; 152:66-70.
81. Machet L, Vaillant L, Lorette G. Follow-up of excision of cutaneous melanoma: sentinel node biopsy, lymph node ultrasound or clinical surveillance alone? Ann Dermatol Venereol 2005; 132:941-944. (Pubitemid 43182444)
82. Murchie P, Delaney EK, Campbell NC, Hannaford PC. GP-led melanoma follow-up: the practical experience of GPs. Fam Pract 2009; 26:317-324.
83. Murchie P. Environmental impact of GP-led melanoma follow up. Br J Gen Pract 2007; 57:837-838. (Pubitemid 47595539)
84. Francken AB, Hoekstra-Weebers JW, Hoekstra HJ. Is GP-led follow-up feasible? Br J Cancer 2010; 102:1445-1446.
85. Murchie P, Hannaford PC, Wyke S, Nicolson MC, Campbell NC. Designing an integrated follow-up programme for people treated for cutaneous malignant melanoma: a practical application of the MRC framework for the design and evaluation of complex interventions to improve health. Fam Pract 2007; 24:283-292. (Pubitemid 47249462)
86. Murchie P, Nicolson MC, Hannaford PC, Raja EA, Lee AJ, Campbell NC. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. Br J Cancer 2010; 102:1447-1455.
87. Brown MD. Office management of melanoma patients. Semin Cutan Med Surg 2010; 29:232-237.
88. McGuire ST, Secrest AM, Andrulonis R, Ferris LK. Surveillance of patients for early detection of melanoma: patterns in dermatologist vs patient discovery. Arch Dermatol 2011; 147:673-678.
89. McKenna DB, Marioni JC, Lee RJ, Prescott RJ, Doherty VR. A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma. Br J Dermatol 2004; 151:636-644. (Pubitemid 39330889)
90. Johnson FE, Virgo KS, Johnson DY, Chan D, Goshima K, Handler BS. Effect of initial tumor stage on patient follow-up after potentially curative surgery for cutaneous melanoma. Int J Oncol 2001; 18:973-978.
91. Collins KK, Fields RC, Baptiste D, Liu Y, Moley J, Jeffe DB. Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol 2011; 18:2925-2936.
92. Siegel R,Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
93. Garbe C. A rational approach to the follow-up of melanoma patients. Recent Results Cancer Res 2002; 160:205-215.
94. Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, Howard K, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 2011; 29:4641-4646.
95. Leiter U, Eigentler TK, Forschner A, Pflugfelder A, Weide B, Held L, et al. Excision guidelines and follow-up strategies in cutaneous melanoma: facts and controversies. Clin Dermatol 2010; 28:311-315.
96. Fields RC, Coit DG. Evidence-based follow-up for the patient with melanoma. Surg Oncol Clin N Am 2011; 20:181-200.
97. Leiter U, Marghoob AA, Lasithiotakis K, Eigentler TK, Meier F, Meisner C, Garbe C. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res 2009; 19:50-57.
98. Machet L, Perrinaud A, Giraudeau B. Routine ultrasonography in melanoma follow-up? Lancet Oncol 2005; 6:2.
99. McEwan L, Smith JG, Matthews JP. Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. Plast Reconstr Surg 1990; 86:527-534. (Pubitemid 20266670)
100. Mocellin S, Nitti D. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist 2011; 16:896-903.
101. Chang SB, Askew RL, Xing Y,Weaver S, JE Gershenwald, Lee JE, et al. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol 2010; 17:2764-2772.
102. Ekwueme DU, Guy GP Jr., Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol 2011; 65:S133-S143.
103. Wong SL. Surveillance chest X-rays for melanoma: prescription or proscription? Ann Surg Oncol 2009; 16:552-553.
104. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, Hunter JA. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140:249-254. (Pubitemid 29111351)
105. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011; 103:129-142.
106. Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol 2001; 19:2844-2850. (Pubitemid 32538193)
107. Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 2009; 16:571-577.
108. Virgo KS, Chan D, Handler BS, Johnson DY, Goshima K, Johnson FE. Current practice of patient follow-up after potentially curative resection of cutaneous melanoma. Plast Reconstr Surg 2000; 106:590-597. (Pubitemid 30666299)